The CARDERA trial randomized @ early active RA patients to receive : ( @ ) methotrexate , ( @ ) methotrexate/ciclosporin , ( @ ) methotrexate/prednisolone or ( @ ) methotrexate/ciclosporin/prednisolone in a factorial-design .